CHC MontLegia — Clinical Trial Site

124 Registered trials

65 Currently recruiting

Organisation

CHC MontLegia

Location

Liege, Belgium

Identifier

ORG-100043333

Address

Boulev. De Patience Et Beajonc 2, 4000, Belgium

Departments

#1003: medical oncology
032005: Pediatric gastroenterology
032007:Oncologie - Hémato-Immunopatho
Breast Hemoto-oncology clinic
Cardiology
Cardiology Department
Center for Reproductive Medicine
Département d'Oncologie/Hématologie
Département d'Oncologie/Hématologie Adulte
Département de Pédiatrie
Department Hématologie et oncologie pédiatrique
Department of Gastroenterology
Department of hemato-oncology
Department of Oncology
Department of Pediatric Hemato-Oncology
Gastro-entérologie
Gastro-enterology
Gastro-enterology and hemato-oncology
Gastro-oncology
Gastroenterology
Gastropediatric
Gastropediatric department
Groupe Sante CHC - Clinique du MontLegia
Groupe Santé CHC Montlégia
Gynécologie-obstétrique
Gynecology
Hémato - oncologie pédiatrique
Hemato - Oncology
Hemato Oncology
Hemato-Oncologie
Hemato-Oncology
Hematology
Hematology Department
Intensive care
Interventional cardiology and intensive care
Medical Oncology
NA
Neonatal Intensive Care Unit
Néphrologie pédiatrique
Neurolog
Neurology
Neurology Department
Oncologie
Oncologie médicale
Oncology
Oncology - Hematology Department
Oncology for pediatrics
Paediatric haemato oncology
Paediatric haemato-oncology
Paediatric Haematology and oncology
Pediatric Cardiology
Pediatric Haemato-oncology
Pediatric Hemato-Oncology
Pediatric hematology and oncology
Pediatric Oncology and Hematology
Pediatrics
Pediatry
Pulmonology

Clinical trials at this site (124)

Search interface

ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised

2022-500535-36-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Medulloblastoma 10
Clinical study to check the Efficacy and Safety of Mitapivat in Patients with Sickle Cell Disease Pending

2024-515202-84-00 Anemia in subjects with sickle cell disease (SCD) 10
Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending

2024-517133-40-00 newly diagnosed, non-metastatic, SHH-activated, TP53-wt 5
BALLAD Belgium - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. The Belgian component of… Pending

2024-518349-85-01 small bowel adenocarcinoma 5
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Relapsed Refractory Multiple Myeloma 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole Pending

2025-524995-53-00 Women with endometriosis undergoing IVF/ICSI 6
A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults… Recruiting

2024-519830-22-00 Heart failure due to systemic left ventricular systolic 5 2026-04-27
A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting

2024-513911-28-00 Acute Ischemic Stroke 10 2026-03-04
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting

2023-508804-39-00 Ulcerative Colitis or Crohn’s Disease 5 2025-10-15
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe… Recruiting

2024-520209-38-00 Obesity or Overweight 5 2025-09-19
Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting

2023-503188-40-00 Active Ulcerative Colitis or Crohn’s Disease 5 2025-01-06
Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis… Recruiting

2022-502050-14-00 Crohn's disease 5 2024-06-04
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit… Recruiting

2023-505000-27-01 newly diagnosed pediatric FLT3-ITD positive and NPM1 wi 4 2023-12-29
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting

2023-505638-82-00 Atypical Hemolytic Uremic Syndrome (aHUS) 5 2022-01-12
A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos… Recruiting

2022-502784-37-00 Prevention of Herpes Zoster in immunocompromised subjec 4 2019-09-03
A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting

2024-520014-22-00 Locally advanced/metastatic urothelial carcinoma 5 2026-04-22
SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study Recruiting

2025-521560-36-00 Type 1 Diabetes 4 2026-04-22